Association between APE1 T1349G polymorphism and prostate cancer risk: evidence from a meta-analysis

Abstract

APE1 T1349G polymorphism was considered to be associated with risk of cancer, but studies on the association between APE1 T1349G polymorphism and risk of prostate cancer remained inconclusive. A meta-analysis of published studies was performed to precisely assess the association between APE1 Asp148Glu polymorphism and prostate cancer risk. PubMed, Embase, and Wanfang databases were searched for published case-control studies investigating the association between APE1 T1349G polymorphism and prostate cancer risk. Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were used to assess the strength of the association. Overall, seven studies with a total of 3,063 individuals were finally included into the meta-analysis. The heterogeneity analysis did not find obvious heterogeneity among those included studies. Meta-analysis of total seven studies did not find an obvious association between APE1 T1349G polymorphism and prostate cancer risk (G vs T OR (95 % CI) = 1.11 (0.99-1.24); GG vs TT OR (95 % CI) = 1.25 (0.96-1.62); TG vs TT OR (95 % CI) = 1.11 (0.95-1.30); GG/TG vs T OR (95 % CI) = 1.13 (0.97-1.32); GG vs TT/TG OR (95 % CI) = 1.16 (0.91-1.48)). Subgroup analyses by ethnicity showed that APE1 T1349G polymorphism was associated with increased risk of prostate cancer in Caucasians (G vs T OR (95 % CI) = 1.26 (1.02-1.56), P = 0.033; TG vs TT OR (95 % CI) = 1.44 (1.06-1.94), P = 0.019; GG/TG vs T OR (95 % CI) = 1.45 (1.08-1.94), P = 0.013). The meta-analysis suggests that APE1 T1349G polymorphism is associated with increased risk of prostate cancer, especially in Caucasians. More studies are needed to further identify the obvious association above.

Association between the APEX1 Asp148Glu polymorphism and prostate cancer, especially among Asians: a new evidence-based analysis

“…In contrast to previous meta-analyses [31–32], this study discovered a significant relationship between the APEX1 Asp148Glu polymorphism and Pca risk in the pooled results (dominant model: OR = 1.159, 95%CI = 1.000-1.344, I 2 = 37.40%, statistical power = 70.90%) (Figures 2–3, Table 2). In order to identify the possible association, a subgroup analysis was conducted.…”

“…At this stage, the samples were divided into subjects of Asian descent, mixed descent and African descent. Although there were no positive results in the African group, our results suggested that the APEX1 Asp148Glu polymorphism was significantly related to Pca in the subjects of mixed descent (dominant model: OR = 1.450, 95%CI = 1.081-1.943, I 2 = 0.00%; per-allele analysis: OR = 1.261, 95%CI = 1.019-1.559, I 2 = 32.00%), which had been demonstrated previously [32](Figure 2, Table 2). Meanwhile, a potential association between the APEX1 Asp148Glu polymorphism and Pca risk among subjects of Asian descentwas also discovered, which had not been reported before (co-dominant model (GG vs .…”

“…Secondly, in our meta-analysis, the ethnicities of the subjects were divided into three parts (Asian descent, mixed descent and African descent) in order to understand the association between APEX1 polymorphisms and Pca more in more detail in different populations. After the analysis, a potential relationship was found among the mixed descent subjects (a mix of European descent, African descent, and others) and subjects of Asian descent, which had not been reported in the previous studies [31–32]. In addition, we also conducted an additional valuable analysis, which was mainly focused on the function of the APE1 polymorphism in the development of Pca.…”

“…However, this conclusion was controversial. In 2014, Li et al investigated the association between rs1130409 and Pca [32]. Then, based on the same data, a new meta-analysis was conducted, which had discovered the other association in special ways [31].…”

“…However, there were no publically available GWAS databases, and GWAS analysis had evaluated this SNP and Pca outcomes before. Recently, two meta-analyses were conducted that showed a significant association between the APEX1 Asp148Glu polymorphism and Pca, especially among Caucasian subjects and the hospital-based population [31–32]. In order to discover the real association, this analysis was conducted.…”